Brief: Astellas Pharma Inc- Notice Regarding Progress In Core Business, Impairment Loss And Revision Of Financial Forecasts For Fy2024
24/01/2025 07:14
Astellas Pharma Inc 4503.T :
* ASTELLAS PHARMA INC- NOTICE REGARDING PROGRESS IN CORE
BUSINESS,
IMPAIRMENT LOSS AND REVISION OF FINANCIAL FORECASTS FOR FY2024
Source text: ID:nTSmx87802
Further company coverage: 4503.T
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)